Laboratory analysis of acylcarnitines, 2020 update: a technical standard of the American College of Medical Genetics and Genomics (ACMG)


Acylcarnitine analysis is a useful test for identifying patients with inborn errors of mitochondrial fatty acid β-oxidation and certain organic acidemias. Plasma is routinely used in the diagnostic workup of symptomatic patients. Urine analysis of targeted acylcarnitine species may be helpful in the diagnosis of glutaric acidemia type I and other disorders in which polar acylcarnitine species accumulate. For newborn screening applications, dried blood spot acylcarnitine analysis can be performed as a multiplex assay with other analytes, including amino acids, succinylacetone, guanidinoacetate, creatine, and lysophosphatidylcholines. Tandem mass spectrometric methodology, established more than 30 years ago, remains a valid approach for acylcarnitine analysis. The method involves flow-injection analysis of esterified or underivatized acylcarnitines species and detection using a precursor-ion scan. Alternative methods utilize liquid chromatographic separation of isomeric and isobaric species and/or detection by selected reaction monitoring. These technical standards were developed as a resource for diagnostic laboratory practices in acylcarnitine analysis, interpretation, and reporting.


Acylcarnitine profile (ACP) analysis is performed for the biochemical detection of disorders of mitochondrial fatty acid β-oxidation (FAO) and organic acid metabolism.1,2 ACP results can be diagnostic for some disorders, such as medium-chain acyl-CoA dehydrogenase (MCAD) deficiency; however, additional testing may be needed in other cases to obtain a precise diagnosis.1,2,3 The conditions revealed by acylcarnitine analysis have in common the accumulation of short, medium, and/or long-chain acyl-CoA species, which are substrates for one of several carnitine acyl-CoA transferases expressed in different intracellular compartments.4,5 The resulting acylcarnitine species are measured in the following clinical situations: (1) evaluation of symptomatic patients, (2) evaluation of asymptomatic (at-risk) siblings of known patients, (3) newborn screening and follow-up testing, (4) prenatal diagnosis, (5) postmortem evaluation.

Laboratories providing this analysis as a clinical service most often do so using flow-injection analysis–tandem mass spectrometry (FIA-MS/MS) as the analytical platform.6,7 Newer MS/MS methods that include a liquid chromatographic (LC) step to separate isobars and isomers are also used.8,9,10,11,12 Other reported methodologies include gas chromatography–mass spectrometry (GC-MS),13 radio high-performance LC,14,15 and capillary electrophoresis.16 As is the case for all complex metabolic profiles, appropriate acylcarnitine analysis requires both analytical proficiency and in-depth interpretation of results with informative reporting.


ACP analysis detects disorders of mitochondrial FAO and organic acid metabolism. Examples of disorders that may be detected by acylcarnitine analysis are listed in Tables 1 and 2. Inborn errors of mitochondrial FAO disorders may present at any age, from birth to adulthood. They are associated with life-threatening episodes of metabolic decompensation after a period of inadequate caloric intake and/or intercurrent illness. Typical manifestations may include hypoketotic hypoglycemia, liver disease, skeletal myopathy and cardiomyopathy, and sudden unexpected death.17 ACP abnormalities have also been described in peroxisomal disorders associated with impaired very long–chain fatty acid (VLCFA) β-oxidation.18,19 However, this latter group of disorders are better diagnosed by plasma VLCFA and branched-chain fatty acid analysis.20

Table 1 Inborn errors of metabolism detected by acylcarnitine profile analysis.
Table 2 Inborn errors of metabolism detected by acylcarnitine profile analysis.

Organic acidemias are a heterogeneous group of inborn errors of metabolism (IEM).21 Classic organic acidemias typically present with recurrent episodes of acute life-threatening illness, hypo- or hypertonia, failure to thrive, and developmental delay. Common acute manifestations include vomiting, lethargy, coma, and seizures.

With rare exceptions, the diagnosis of these conditions is almost exclusively a laboratory process, of which acylcarnitine analysis is a key component. A comprehensive metabolic evaluation may also include the analysis of plasma amino acids, urine organic acids, and plasma carnitine (free and total). Depending on the results of these studies, additional testing may be warranted.


The combined incidence of these disorders is estimated to be between 1:5,000 and 1:10,000 live births.22


A majority of IEM detectable by acylcarnitine analysis are inherited as autosomal recessive traits. Two X-linked disorders are potentially detected by acylcarnitine analysis. The first is HSD10 mitochondrial disease (MIM 300438), which is caused by a deficiency of a mitochondrial ribonuclease P subunit, encoded by HSD17B10 (MIM 300256). This multifunctional protein has dehydrogenase activity toward a range of substrates, including 2-methyl-3-hydroxybutyryl-CoA.23 The second is cobalamin disorder type X (MIM 309541), caused by a deficiency of a global transcriptional coregulator encoded by HCFC1.24,25 It should be noted that acylcarnitine analysis may have low sensitivity for detecting HSD10 mitochondrial disease,23 and the sensitivity of acylcarnitine analysis to detect cobalamin disorder type IX has not been fully evaluated.


This laboratory technical standard was informed by a review of the literature, including any current guidelines, and expert opinion. Resources consulted included PubMed (search terms: acylcarnitine quantitation, acylcarnitine analysis, separation, UPLC, peroxisomal, prenatal, urine), Clinical and Laboratory Standards Institute (CLSI) guidelines26,27,28 and CLIA regulations, and the Centers for Disease Control and Prevention (CDC) Morbidity and Mortality Weekly Report on Good Laboratory Practices for Biochemical Genetics Testing and Newborn Screening for Inherited Metabolic Disorders.29 When the literature provided conflicting evidence about a topic or when there was insufficient evidence, the authors used expert opinion to inform the recommendations. Expert opinion included the coauthors of the document, members of the Biochemical Genetics Subcommittee of the Lab QA Committee, as well as the experts consulted outside the workgroup and acknowledged in this document. Any conflicts of interest for workgroup members or consultants are listed. The American College of Medical Genetics and Genomics (ACMG) Laboratory Quality Assurance Committee reviewed the document providing further input on the content, and a final draft was delivered to the ACMG Board of Directors for review and approval to send out for member comment. The final draft of the document was posted on the ACMG website and an email link was sent to ACMG members inviting all to provide comment. All members’ comments were assessed by the authors; additional evidence was also included, and our recommendations were amended as deemed appropriate. Member comments and author responses were reviewed by a representative of the Laboratory Quality Assurance Committee and the ACMG Board. The final document was approved by the ACMG Board of Directors. This updated standard replaces the previous document “Acylcarnitine profile analysis” by Rinaldo et al.30


Specimen requirements

Carnitine and its esters are found in virtually all biological fluids. The clinical utility of an acceptable biological fluid will depend upon the purpose of the analysis. Concentrations of acylcarnitine species vary between sample types and plasma concentrations may not be reflective of tissue concentrations.10 Typical volumes of different sample types are shown in Table 3.

Table 3 Typical sample testing volumes for acylcarnitine profile analysis.


Heparinized plasma is the preferred sample type for the diagnostic evaluation of symptomatic patients and asymptomatic at-risk individuals. EDTA plasma or serum may also be accepted by testing laboratories as alternative sample types.

Dried blood spot

Dried blood spots (DBS) are used for newborn screening, and have utility in the clinical diagnostic setting, providing an alternative to plasma. In comparison with plasma or serum, blood spots have higher concentrations of long-chain acylcarnitines and certain other species such as C2, C3, C4-DC, and C5-OH, and lower free carnitine (C0).31 DBS may therefore have a greater sensitivity for detecting carnitine palmitoyltransferase (CPT) IA deficiency (MIM 255120), a disorder characterized by reduced concentrations of long-chain acylcarnitines and elevated free carnitine.31 In contrast, plasma may have greater sensitivity for diagnosing disorders associated with an accumulation of long-chain acylcarnitines, such as CPT II deficiency (MIM 600649, 608836, 255110) and mitochondrial trifunctional protein deficiency (MIM 609015).31,32

Bile or bile spot

Postmortem screening can be performed in bile as a first-level evaluation for sudden or unexpected death.33,34 Bile can be spotted onto filter paper and analyzed in the same manner as DBS.


Urinary acylcarnitine analysis can be useful in the workup of organic acidemias and FAO disorders35 associated with accumulations of short- or medium-chain acylcarnitine species,36,37,38,39 which are efficiently excreted in the urine. This is most often applied in the case of glutaric acidemia type I, in which an elevation of glutarylcarnitine may be more readily discernible in urine compared with DBS or plasma.39 Long-chain acylcarnitines have low solubility and hence low concentrations in urine; urinary acylcarnitine analysis is not helpful for the diagnosis of long-chain mitochondrial FAO disorders. However, utility for diagnosing patients with certain peroxisomal disorders has been suggested.19 In patients with peroxisomal biogenesis disorders and D-bifunctional protein deficiency, an increase was reported in urinary long-chain dicarboxylic acid acylcarnitines, and to a lesser extent in very long–chain monocarboxylic acid species.19

Cultured fibroblasts

ACP performed in cultured fibroblasts incubated with fatty acid substrates and carnitine can be useful for the diagnosis of FAO disorders.2,40,41

Amniotic fluid

Acylcarnitine analysis in amniotic fluid has been used for the prenatal diagnosis of certain IEM.42,43 This testing may be useful when there is a family history of IEM and molecular studies were not obtained or were uninformative in the proband, and when performed in combination with one or more additional independent tests.1

Conditions of sample collection, shipping, handling, and storage

Plasma, serum, whole blood, and urine samples collected at the time of acute illness have the greatest sensitivity for detecting fatty acid oxidation disorders and organic acidemias. At ambient temperature, plasma acylcarnitines are stable for less than two days and in DBS for less than two weeks. At colder temperatures, specimens may be preserved for longer. Short-chain species are more unstable compared with long-chain species. Performing laboratories should define appropriate handling, shipping, and storage guidelines for their specific application.

Exogenous variables

Dietary factors such as medium-chain triglyceride (MCT)–containing formulas, fasting, ketogenic diet, carnitine supplementation, and total parenteral nutrition may influence acylcarnitine profiles. Carnitine insufficiency lowers the concentrations of acylcarnitines in body fluids and may decrease the sensitivity of ACP testing. Conversely, carnitine supplementation enhances blood concentrations and urinary excretion of acylcarnitines,38 and may complicate interpretation of profiles. Renal impairment may cause an increase in short and medium-chain dicarboxylic acid acylcarnitine species (S. Young, unpublished observations, DUHS Biochemical Genetics Laboratory), whereas liver dysfunction may cause an increase in long-chain dicarboxylic acid acylcarnitine species.6

Clinical indications for testing

There are a variety of clinical indications for ACP analysis. Most commonly, ACP analysis is obtained following an abnormal newborn screen. ACP analysis can be helpful when an organic acidemia is suspected; findings often include metabolic acidosis, poor feeding, and lethargy or encephalopathy. Note that for an organic acidemia, urine organic acid analysis is the preferred method for diagnosis.44 For disorders of fatty acid oxidation, typical clinical indications include hypoglycemia (in the absence of ketonuria), rhabdomyolysis, and cardiomyopathy. ACP analysis should also be considered in the setting of low free carnitine, to evaluate for the possibility of secondary carnitine deficiency, as well as in cases where the acyl to free carnitine ratio is elevated.

Due to an increased risk of long-chain 3-hydroxyacyl-CoA dehydrogenase or trifunctional deficiency, and possibly other fatty acid oxidation disorders, ACP analysis may be obtained in neonates with maternal complications of acute fatty liver of pregnancy and/or hemolysis, elevated liver enzymes, and low platelet count (HELLP syndrome).45,46 Both CPT II deficiency and multiple acyl-CoA dehydrogenase deficiency (MADD) can present in the neonatal period with cystic kidneys and other malformations;47 as these early presentations are often fatal, it is imperative to obtain the correct diagnosis for genetic counseling.

ACP analysis should be considered in cases of sudden infant death or other unexpected death at any age, particularly if there was fasting or vomiting in the preceding hours, a history of Reye syndrome, or if fatty infiltration of the liver is noted on autopsy. ACP analysis may be obtained in first-degree relatives following the diagnosis of an FAO disorder or organic acidemia in the proband. Finally, ACP analysis may be followed over time in patients with known disorders of fatty acid oxidation or organic acidemias for monitoring the disease and compliance with treatment.


Sample preparation

Acylcarnitine analysis may be performed as a dedicated standalone diagnostic test, or as a component of a multiplexed method for newborn screening that includes analysis of other analytes such as amino acids, succinylacetone, guanidinoacetate, creatine, and very long–chain lysophospholipids.7,48,49 Acylcarnitines are most often analyzed as butyl-esters,2 methyl-esters,32 or without derivatization.49 Esterification of the carboxylic acid groups results in a fixed quaternary positive charge on the carnitine moiety of acylcarnitine species. This increases the sensitivity of the method in positive-ion mode, especially for dicarboxylic acids. However, this approach requires specimen heating under acidic conditions, resulting in hydrolysis of acylcarnitine ester bonds, reducing the levels of acylcarnitines and increasing the pool of free carnitine.50 Therefore, the derivatization conditions must be carefully controlled to minimize loss of acylcarnitines. The use of stable-isotope internal standards is also important to compensate for any losses that do occur.

Plasma specimens are diluted with a mixture of deuterium-labeled internal standards dissolved in aqueous organic solvent mixtures, with or without organic acid modifiers (e.g., formic acid). Commonly used internal standards include [2H3]-labeled C2, C3, C4, C8, C14, C16; [2H9]-labeled C5 and C14; and [2H6]-C5-DC. Other internal standards can be used, but care must be taken not to interfere with the signal of a clinically relevant species (e.g., the butyl-ester of d3-C6 at m/z 319 is only 1 Da from m/z 318, the molecular ion of hydroxyisovalerylcarnitine). Samples are centrifuged to remove protein precipitate and the supernatant containing extracted acylcarnitines is transferred to another tube and dried under nitrogen. Acylcarnitines are derivatized to their butyl-esters with 3 M HCl in n-butanol and heating at 65 °C for 15 minutes. Samples are again dried under nitrogen and reconstituted with a solvent matrix. DBS are similarly prepared; acylcarnitines are extracted from one or more punches from the spot using methanol or acetonitrile containing internal standards.

Analytical methods

Flow-injection analysis–tandem mass spectrometry with precursor-ion scan

Acylcarnitine analysis by FIA positive-ion electrospray–tandem mass spectrometry (MS/MS) utilizes a precursor-ion scan to separate mono- and dicarboxylic acid species, 2 to 18 carbons in length. Butylated and underivatized acylcarnitines are detected by precursors of m/z 85 with a scan from approximately m/z 200 to 500. Methylated acylcarnitines are detected using a precursor-ion scan of m/z 99. This mode of detection confers sufficient sensitivity and specificity to the method without the need for chromatographic separation, allowing for a rapid analysis. FIA combined with a precursor-ion scan has several advantages over methods that utilize a selected reaction monitoring (SRM) mode of detection, with or without chromatography. The whole profile of acylcarnitine species with masses within the scan range can be evaluated. Additionally, common drug artifacts, interfering compounds, and evidence of poor derivatization can be more readily detected. For example, the parent-product ion pair for butylated C4-acylcarnitine species (m/z 288 > 85) can have a contribution from the [M + 1] isotope of butylated formiminoglutamate, which has a [M + H]+ of m/z 287.51 A contribution from glutamate to the m/z 260 > 85 transition can result in an inaccurate quantification of acetylcarnitine (C2) by the butylation method.52 The use of a more specific transition (m/z 260 > 141) can be used to more accurately quantify butylated acetylcarnitine.53 Flow-injection methods do not allow separation of isomeric and isobaric species, which limits the diagnostic specificity of profiles generated by these methods. However, when performed in combination with other tests, such as urine organic acid or acylglycine analysis, the differential diagnosis suggested by flow-injection acylcarnitine profiles can usually be discerned. The isobaric pairs differ depending on the derivatization method (Supplemental Table 1). For example, C3-DC and C4-OH are isobaric by the underivatized method, C3-DC and C5-OH by the methylation method, and C5-DC and C10-OH by the butylation method. With flow-injection methods, when there is an elevated signal for an isobaric pair, a reflex test using an alternative derivative can be used to identify which acylcarnitine species are elevated. Acylcarnitine species and the corresponding mass of the derivatized (butylated or methylated) or nonderivatized molecular ions are listed in Supplemental Table 1. Tolerance limits for the identification by mass must be defined by the laboratory.

LC-MS/MS methods

Liquid chromatography methods are used to enable more sensitive and specific acylcarnitine identification. In this approach, specimens are subjected to LC prior to MS/MS identification with the goal of separating isomeric or isobaric acylcarnitines and interferents. These methods can be performed on underivatized specimens, simplifying sample preparation and allowing concurrent quantification of free carnitine. Reversed phase LC generates the highest chromatographic resolution of acylcarnitines,8,9 but hydrophilic interaction liquid chromatography (HILIC) methods have also been described that provide relatively rapid analysis times with simple sample preparations.10,11 LC-MS/MS acylcarnitine chromatograms are highly complex in comparison with flow-injection profiles. For example, C8-carnitine alone has 26 different hypothetical structural isomers, each potentially having unique chromatographic properties.12 Numerous other acylcarnitines have one or more chiral centers, including all hydroxylated acylcarnitines. These enantiomeric compounds generate multiple peaks by some LC-MS/MS methods.9 Pure analytic standards are not available for the majority of these compounds, challenging the confident assignment and quantification of the full range of acylcarnitines potentially detectable by LC-MS/MS methods. Even fewer isotopically labeled acylcarnitine standards exist, making it difficult to account for matrix effects. Considering these challenges, chromatographic methods are best used in the setting of focused reflex testing or research studies.


Each laboratory must validate the performance characteristics of their specific analytical protocol and periodically verify its performance in accordance with local regulations. In the United States, this includes CLIA and the College of American Pathologists (CAP) requirements. Examples of published method validation approaches are provided by CLSI in several different documents (e.g., C24-A3: Statistical Quality Control for Quantitative Measurement Procedures: Principles and Definitions, 4th edition27 and C26-A: Liquid Chromatography–Mass Spectrometry Methods; Approved Guidelines28) and ACMG technical standards, such as this one. Laboratories should also devise procedures to address analytical values outside of their established criteria for performance and for clinical specimens with ambiguous stability.

Calibration and quantitation

Stable-isotope internal standards are available from a variety of commercial sources. These standards must be validated by determining their recoveries from weighed, nonisotopic acylcarnitine standards for as many analytes as possible. Internal standards must be periodically revalidated at a regular frequency to account for natural decay. Reference standards are not available for all acylcarnitine species detected by a profile analysis, such as the hydroxylated acylcarnitine species. Quantitation of these compounds should be extrapolated by application of the calibration for the nearest species of similar structure and m/z. The laboratory should determine their method’s linear range, analytical measurement range, and lower limit of detection for all clinically informative acylcarnitines, when possible. These performance characteristics should be verified on a regular basis as specified by CLIA.

Reference intervals

Laboratory-specific, age-appropriate reference intervals for all reported acylcarnitines should be established and periodically validated per applicable regulations (e.g., CLSI EP28-A3c: Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory, Approved Guideline, 3rd edition).26 When literature-based intervals are used, they must be verified by the laboratory before implementation. For all applications, reference intervals should be established on the appropriate tissue, collection tube, and matrix. For instance, the comparison of a pediatric result to a blood spot, plasma, or serum normative interval derived from an adult population is inappropriate. Free carnitine and short-chain acylcarnitine species are increased in postmortem blood samples34 and reference intervals for this sample type should be generated using postmortem control samples.

Instrument quality cross-check

When more than one mass spectrometric instrument is used to complete quantitative analyses for acylcarnitines, instrument comparisons should be routinely performed, and compatibility confirmed at regular intervals. This comparison should include instruments implemented as a backup for emergency analyses. The process to confirm acceptable performance can include quality control (QC) comparisons, proficiency testing (PT) evaluations, or interlaboratory comparisons at the laboratory’s discretion.

Testing personnel

Appropriate training and ongoing competency requirements for laboratory personnel performing ACP analysis must be established and documented. MS/MS-based applications, instrument optimization, method validation, and clinical testing must be performed by personnel with specialized training in the operation of MS/MS.

Quality control

A positive and negative control should be prepared and analyzed with every batch of patient samples tested. The internal standard mix should also be analyzed separately with each batch.

A QC program based on the quantitative analysis of normal and abnormal control specimens should be implemented on a regular basis. Target ranges for QCs should be established for each metabolite and used to accept or reject a given run. The internal standards in each specimen serve as a QC check for each specimen. The use of Westgard rules for clinical specimen analysis further controls the parameters for quality patient diagnosis and reporting.54 A laboratory director or designee should perform a monthly review and approval of control values.

Proficiency testing

Laboratories should participate in a PT program at time intervals as required by regulating agencies. PT performance should be monitored and insufficiencies requiring further investigation identified. Remedial action for laboratories uncovered by PT performance should be documented. The CAP provides a commercially available, external proficiency testing service for quantitative plasma acylcarnitine analysis. The European Research Network for Evaluation and Improvement of Screening, Diagnosis and Treatment of Inherited Disorders of Metabolism (ERNDIM) also has a PT scheme for plasma and DBS acylcarnitines. The CDC provides a PT scheme for DBS. Scheduled interlaboratory comparison (alternative PT) can be used when external proficiency testing is unavailable for certain tissues and matrices.



Results should be reviewed and interpreted by an ABMGG-certified biochemical geneticist or other qualified individual. Informative results are usually characterized by a pattern of one or more elevated acylcarnitine species in comparison with age-matched reference ranges. Interpretation of results is based on pattern recognition, rather than on individual abnormal values (see Fig. 1). The differential diagnosis of abnormal results of species potentially representing multiple isomers (C4, C5, C5-OH) is critical and cannot be overstated.2,3 Basic acylcarnitine patterns associated with various disease states are listed in Fig. 1. In addition to the primary markers listed, calculation of ratios is useful in the interpretation of abnormal results (Fig. 1). Examples of commonly used ratios include C3/C2, which is elevated in propionic and methylmalonic acidemia and related disorders; C8/C10, which is elevated in MCAD deficiency; and C14:1/C12:1, which is elevated in very long–chain acyl-CoA dehydrogenase (VLCAD) deficiency, although mild elevations of this ratio may also be observed in long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) and trifunctional protein (TFP) deficiencies, and in ketosis. Informative profiles may not always be detected in disorders where the accumulation of diagnostic species is a reflection of the residual activity of the defective enzyme, the dietary load of carnitine and precursors, and the anabolic or catabolic status of the patient. Modest abnormalities should be correlated to the patient’s carnitine levels as a status of carnitine insufficiency could affect the outcome of this analysis. It is important to correlate ACP results with other laboratory findings, such as the urine organic acid profile and routine chemistries, and the demographic and clinical status of the patient. For instance, in premature infants, elevations of short and medium-chain dicarboxylic acid species may be observed, presumably secondary to renal immaturity. In adults with late-onset CPT II or VLCAD deficiency that presents as a myopathic phenotype, elevations of long-chain species can be subtle.

Fig. 1: Common acylcarnitine patterns associated with various disease states.

H high, H? high but specific isomeric species are not clearly defined for this disorder, L low, V level varies from high-normal to elevated, *In CUD other acylcarnitine species are generally low. **C14:1/C12:1 is typically in the high-normal range or slightly elevated (< 3). ***For many listed disorders, C0 can be low due to secondary carnitine depletion. ****Low C2 may also be observed in other fatty acid oxidation and amino acid metabolism disorders, secondary to factors such as low flux through the β-oxidation pathway, and/or carnitine depletion. Note, in SUCLA2 deficiency, C4-DC elevations were shown to be succinylcarnitine, whereas methylmalonylcarnitine was within normal reference limits.60 1: CUD carnitine uptake deficiency, 2: CPT1A carnitine palmitoyltransferase I deficiency, 3: PA propionic acidemia, 4: MMA methylmalonic acidemia, 5: SUCLA succinyl-CoA ligase deficiency, 6: SCAD short-chain acyl-CoA dehydrogenase, 7: EE ethylmalonic encephalopathy, 8: IBD isobutyryl-CoA dehydrogenase deficiency, 9: IVA isovaleryl-CoA dehydrogenase deficiency, 10: SBCAD short/branched-chain acyl-CoA dehydrogenase deficiency, 11: HADH 3-hydroxyacyl-CoA dehydrogenase, 12: HIBCH 3-hydroxyisobutyryl-CoA hydrolase deficiency, 13: 3-MCC 3-methylcrotonyl-CoA carboxylase deficiency, 14: HMG HMG-CoA lyase deficiency, 15: BIO biotinidase or holocarboxylase synthetase deficiency, 16: 3MG 3-methylglutaconyl-CoA hydratase deficiency (AUH), 17: BKT β-ketothiolase deficiency, 18: MHBD 2-methyl-3-hydroxybutyryl-CoA dehydrogenase deficiency, 19: MCT supplementation with medium-chain triglycerides, 20: MCAD medium-chain acyl-CoA dehydrogenase deficiency, 21: Malonic aciduria malonyl-CoA decarboxylase deficiency, 22: GA1 glutaric aciduria type 1, 23: NADK2 dienoyl-CoA reductase deficiency caused by mitochondrial NAD kinase 2 deficiency, 24: VLCAD very long–chain acyl-CoA dehydrogenase deficiency, 26: CPT II/CACT carnitine palmitoyltransferase II/carnitine-acylcarnitine translocase deficiency, 27: LCHAD/TFP long-chain L-3-hydroxyacyl-CoA dehydrogenase/trifunctional protein deficiency, 28: MAD multiple acyl-CoA dehydrogenase deficiency.

Several drugs may induce or mimic abnormal levels of one or more known acylcarnitine species;55,56 these include pivalic acid (a C5 isomer), valproic acid (a C8 isomer), cefotaxime (a C16:1-OH isobar by the butyl-ester method). Other exogenous compounds could result in the appearance of atypical species, some of them at m/z values in close proximity to or even overlapping acylcarnitines of diagnostic significance. Examples include 2-ethylhexanoic acid from plasticizers used in tubing used for extracorporeal membrane oxygenation and other procedures,57 and intravenous fluids containing dextrose.58 Dietary artifacts are also possible, usually related to food intake enriched with fatty acids (MCT oil, ketogenic diet).59


Important elements to include in patient reports are appropriate patient and specimen information, analyte values reported against reference limits, and interpretive comments. As discussed above, interpretations should integrate other lab findings (e.g., organic acids, free and total carnitine, and/or amino acids), and take into consideration the clinical and dietary history, when applicable and available. When abnormal results are detected, the interpretation should include an overview of the results and their significance, quantitative results with age-appropriate reference ranges, a correlation to available clinical information, elements of differential diagnosis, recommendations for additional biochemical testing and in vitro confirmatory studies (e.g., enzymatic analysis, molecular analysis), and a phone number to reach the reporting laboratory with additional questions.


  1. 1.

    Pasquali M, Longo N. Newborn screening and inborn errors of metabolism. In: Rifai N, Horvath AR, Wittwer C, editors. Tietz textbook of clinical chemistry and molecular diagnostics. 6th ed. St. Louis: Elsevier; 2018. p. 1697–1730.

  2. 2.

    Matern D. Acylcarnitines, including in vitro loading tests. In: Blau N, Duran M, Gibson KM, editors. Laboratory guide to the methods in biochemical genetics. Berlin: Springer; 2008. p. 171–206.

  3. 3.

    Sweetman L, Millington DS, Therrell BL, et al. Naming and counting disorders (conditions) included in newborn screening panels. Pediatrics. 2006;117:S308–314.

    PubMed  Article  PubMed Central  Google Scholar 

  4. 4.

    Violante S, Ijlst L, Ruiter J, et al. Substrate specificity of human carnitine acetyltransferase: Implications for fatty acid and branched-chain amino acid metabolism. Biochim Biophys Acta. 2013;1832:773–779.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  5. 5.

    Violante S, Ijlst L, van Lenthe H, de Almeida IT, Wanders RJ, Ventura FV. Carnitine palmitoyltransferase 2: New insights on the substrate specificity and implications for acylcarnitine profiling. Biochim Biophys Acta. 2010;1802:728–732.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  6. 6.

    Millington DS. Tandem mass spectrometry in clinical diagnosis. In: Blau N, Duran M, Blaskovics ME, Gibson K, editors. Physician’s guide to the laboratory diagnosis of metabolic diseases. 2nd ed. Berlin: Springer; 2003. p. 57–75.

  7. 7.

    Chace DH, Kalas TA. A biochemical perspective on the use of tandem mass spectrometry for newborn screening and clinical testing. Clin Biochem. 2005;38:296–309.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  8. 8.

    Minkler PE, Stoll MS, Ingalls ST, Kerner J, Hoppel CL. Validated method for the quantification of free and total carnitine, butyrobetaine, and acylcarnitines in biological samples. Anal Chem. 2015;87:8994–9001.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  9. 9.

    Peng M, Fang X, Huang Y, et al. Separation and identification of underivatized plasma acylcarnitine isomers using liquid chromatography-tandem mass spectrometry for the differential diagnosis of organic acidemias and fatty acid oxidation defects. J Chromatogr A. 2013;1319:97–106.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  10. 10.

    Kivilompolo M, Ohrnberg L, Oresic M, Hyotylainen T. Rapid quantitative analysis of carnitine and acylcarnitines by ultra-high performance-hydrophilic interaction liquid chromatography-tandem mass spectrometry. J Chromatogr A. 2013;1292:189–194.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  11. 11.

    Peng M, Liu L, Jiang M, et al. Measurement of free carnitine and acylcarnitines in plasma by HILIC-ESI-MS/MS without derivatization. J Chromatogr B Analyt Technol Biomed Life Sci. 2013;932:12–18.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  12. 12.

    Minkler PE, Stoll MSK, Ingalls ST, Hoppel CL. Correcting false positive medium-chain acyl-CoA dehydrogenase deficiency results from newborn screening; synthesis, purification, and standardization of branched-chain C8 acylcarnitines for use in their selective and accurate absolute quantitation by UHPLC-MS/MS. Mol Genet Metab. 2017;120:363–369.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  13. 13.

    Costa CG, Struys EA, Bootsma A, et al. Quantitative analysis of plasma acylcarnitines using gas chromatography chemical ionization mass fragmentography. J Lipid Res. 1997;38:173–182.

    CAS  PubMed  PubMed Central  Google Scholar 

  14. 14.

    Kler RS, Jackson S, Bartlett K, et al. Quantitation of acyl-CoA and acylcarnitine esters accumulated during abnormal mitochondrial fatty acid oxidation. J Biol Chem. 1991;266:22932–22938.

    CAS  PubMed  PubMed Central  Google Scholar 

  15. 15.

    Schmidt-Sommerfeld E, Bobrowski PJ, Penn D, Rhead WJ, Wanders RJ, Bennett MJ. Analysis of carnitine esters by radio-high performance liquid chromatography in cultured skin fibroblasts from patients with mitochondrial fatty acid oxidation disorders. Pediatr Res. 1998;44:210–214.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  16. 16.

    Pormsila W, Morand R, Krähenbühl S, Hauser PC. Capillary electrophoresis with contactless conductivity detection for the determination of carnitine and acylcarnitines in clinical samples. J Chromatogr B Analyt Technol Biomed Life Sci. 2011;879:921–926.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  17. 17.

    Houten SM, Violante S, Ventura FV, Wanders RJ. The biochemistry and physiology of mitochondrial fatty acid β-oxidation and its genetic disorders. Annu Rev Physiol. 2016;78:23–44.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  18. 18.

    Rizzo C, Boenzi S, Wanders RJ, Duran M, Caruso U, Dionisi-Vici C. Characteristic acylcarnitine profiles in inherited defects of peroxisome biogenesis: a novel tool for screening diagnosis using tandem mass spectrometry. Pediatr Res. 2003;53:1013–1018.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  19. 19.

    Duranti G, Boenzi S, Rizzo C, et al. Urine acylcarnitine analysis by ESI-MS/MS: a new tool for the diagnosis of peroxisomal biogenesis disorders. Clin Chim Acta. 2008;398:86–89.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  20. 20.

    De Biase I, Tortorelli S, Kratz L, Steinberg SJ, Cusmano-Ozog K, Braverman N. Laboratory diagnosis of disorders of peroxisomal biogenesis and function: a technical standard of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2020;22:686–697.

    PubMed  Article  PubMed Central  Google Scholar 

  21. 21.

    Rinaldo P. Organic acids. In: Blau N, Duran M, Gibson KM, editors. Laboratory guide to the methods in biochemical genetics. Berlin: Springer; 2008. p. 137–169.

  22. 22.

    Watson MS, Lloyd-Puryear MA, Mann MY, Rinaldo P, Howell RR. Newborn screening: toward a uniform screening panel and system, main report. Genet Med. 2006;8:12–252.

    Article  Google Scholar 

  23. 23.

    Zschocke J. HSD10 disease: clinical consequences of mutations in the HSD17B10 gene. J Inherit Metab Dis. 2012;35:81–89.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  24. 24.

    Yu H-C, Sloan JL, Scharer G, et al. An X-linked cobalamin disorder caused by mutations in transcriptional coregulator HCFC1. Am J Hum Genet. 2013;93:506–514.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  25. 25.

    Scalais E, Osterheld E, Weitzel C, et al. X-linked cobalamin disorder (HCFC1) mimicking nonketotic hyperglycinemia with increased both cerebrospinal fluid glycine and methylmalonic acid. Pediatr Neurol. 2017;71:65–69.

    PubMed  Article  PubMed Central  Google Scholar 

  26. 26.

    CLSI. Defining, establishing, and verifying reference intervals in the clinical laboratory; approved guideline. 3rd ed. CLSI document EP28-A3c. Wayne, PA: Clinical and Laboratory Standards Institute; 2008.

  27. 27.

    CLSI. Statistical quality control for quantitative measurement procedures: principles and definitions. 4th ed. CLSI guideline C24. Wayne, PA: Clinical and Laboratory Standards Institute; 2016.

  28. 28.

    CLSI. Liquid chromatography-mass spectrometry methods; approved guideline. CLSI document, C62-A. Wayne, PA: Clinical and Laboratory Standards Institute; 2014.

  29. 29.

    Centers for Disease Control and Prevention. Good laboratory practices for biochemical genetic testing and newborn screening for inherited metabolic disorders. MMWR Recomm Rep. 2012;61:1–44.

    Google Scholar 

  30. 30.

    Rinaldo P, Cowan TM, Matern D. Acylcarnitine profile analysis. Genet Med. 2008;10:151–156.

    PubMed  Article  PubMed Central  Google Scholar 

  31. 31.

    de Sain-van der Velden MGM, Diekman EF, Jans JJ, et al. Differences between acylcarnitine profiles in plasma and bloodspots. Mol Genet Metab. 2013;110:116–121.

    PubMed  Article  CAS  PubMed Central  Google Scholar 

  32. 32.

    Van Hove JL, Kahler SG, Feezor MD, et al. Acylcarnitines in plasma and blood spots of patients with long-chain 3-hydroxyacyl-coenzyme A dehydrogenase defiency. J Inherit Metab Dis. 2000;23:571–582.

    PubMed  Article  PubMed Central  Google Scholar 

  33. 33.

    Rashed MS, Ozand PT, Bennett MJ, Barnard JJ, Govindaraju DR, Rinaldo P. Inborn errors of metabolism diagnosed in sudden death cases by acylcarnitine analysis of postmortem bile. Clin Chem. 1995;41:1109–1114.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  34. 34.

    Chace DH, DiPerna JC, Mitchell BL, Sgroi B, Hofman LF, Naylor EW. Electrospray tandem mass spectrometry for analysis of acylcarnitines in dried postmortem blood specimens collected at autopsy from infants with unexplained cause of death. Clin Chem. 2001;47:1166–1182.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  35. 35.

    Mueller P, Schulze A, Schindler I, Ethofer T, Buehrdel P, Ceglarek U. Validation of an ESI-MS/MS screening method for acylcarnitine profiling in urine specimens of neonates, children, adolescents and adults. Clin Chim Acta. 2003;327:47–57.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  36. 36.

    Oglesbee D, He M, Majumder N, et al. Development of a newborn screening follow-up algorithm for the diagnosis of isobutyryl-CoA dehydrogenase deficiency. Genet Med. 2007;9:108–116.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  37. 37.

    Carrozzo R, Dionisi-Vici C, Steuerwald U, et al. SUCLA2 mutations are associated with mild methylmalonic aciduria, Leigh-like encephalomyopathy, dystonia and deafness. Brain. 2007;130:862–874.

    PubMed  Article  PubMed Central  Google Scholar 

  38. 38.

    Kobayashi H, Hasegawa Y, Endo M, Purevsuren J, Yamaguchi S. ESI-MS/MS study of acylcarnitine profiles in urine from patients with organic acidemias and fatty acid oxidation disorders. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;855:80–87.

    CAS  PubMed  Article  Google Scholar 

  39. 39.

    Tortorelli S, Hahn SH, Cowan TM, Brewster TG, Rinaldo P, Matern D. The urinary excretion of glutarylcarnitine is an informative tool in the biochemical diagnosis of glutaric acidemia type I. Mol Genet Metab. 2005;84:137–143.

    CAS  PubMed  Article  Google Scholar 

  40. 40.

    Shen JJ, Matern D, Millington DS, et al. Acylcarnitines in fibroblasts of patients with long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency and other fatty acid oxidation disorders. J Inherit Metab Dis. 2000;23:27–44.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  41. 41.

    Roe DS, Yang BZ, Vianey-Saban C, Struys E, Sweetman L, Roe CR. Differentiation of long-chain fatty acid oxidation disorders using alternative precursors and acylcarnitine profiling in fibroblasts. Mol Genet Metab. 2006;87:40–47.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  42. 42.

    Bo R, Hasegawa Y, Yamada K, et al. A fetus with mitochondrial trifunctional protein deficiency: Elevation of 3-OH-acylcarnitines in amniotic fluid functionally assured the genetic diagnosis. Mol Genet Metab Rep. 2016;6:1–4.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  43. 43.

    Van Hove JL, Chace DH, Kahler SG, Millington DS. Acylcarnitines in amniotic fluid: application to the prenatal diagnosis of propionic acidaemia. J Inherit Metab Dis. 1993;16:361–367.

    PubMed  Article  PubMed Central  Google Scholar 

  44. 44.

    Gallagher RC, Pollard L, Scott AI, Huguenin S, Goodman S, Sun Q. Laboratory analysis of organic acids, 2018 update: a technical standard of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2018;20:683–691.

    PubMed  Article  PubMed Central  Google Scholar 

  45. 45.

    Ibdah JA, Yang Z, Bennett MJ. Liver disease in pregnancy and fetal fatty acid oxidation defects. Mol Genet Metab. 2000;71:182–189.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  46. 46.

    Liu J, Ghaziani TT, Wolf JL. Acute fatty liver disease of pregnancy: updates in pathogenesis, diagnosis, and management. Am J Gastroenterol. 2017;112:838–846.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  47. 47.

    Hackl A, Mehler K, Gottschalk I, et al. Disorders of fatty acid oxidation and autosomal recessive polycystic kidney disease-different clinical entities and comparable perinatal renal abnormalities. Pediatr Nephrol. 2017;32:791–800.

    PubMed  Article  PubMed Central  Google Scholar 

  48. 48.

    Haynes CA, De Jesús VR. Simultaneous quantitation of hexacosanoyl lysophosphatidylcholine, amino acids, acylcarnitines, and succinylacetone during FIA–ESI–MS/MS analysis of dried blood spot extracts for newborn screening. Clin Biochem. 2016;49:161–165.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  49. 49.

    Asef CK, Khaksarfard KM, De Jesus VR. Non-derivatized assay for the simultaneous detection of amino acids, acylcarnitines, succinylacetone, creatine, and guanidinoacetic acid in dried blood spots by tandem mass spectrometry. Int J Neonatal Screen. 2016;2:13.

    PubMed  PubMed Central  Article  Google Scholar 

  50. 50.

    Johnson DW. Inaccurate measurement of free carnitine by the electrospray tandem mass spectrometry screening method for blood spots. J Inherit Metab Dis. 1999;22:201–202.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  51. 51.

    Malvagia S, La Marca G, Casetta B, et al. Falsely elevated C4-carnitine as expression of glutamate formiminotransferase deficiency in tandem mass spectrometry newborn screening. J Mass Spectrom. 2006;41:263–265.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  52. 52.

    Chace DH, Kalas TA, Naylor EW. Use of tandem mass spectrometry for multianalyte screening of dried blood specimens from newborns. Clin Chem. 2003;49:1797–1817.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  53. 53.

    Scott D, Heese B, Garg U. Quantification of free carnitine and acylcarnitines in plasma or serum using HPLC/MS/MS. Methods Mol Biol. 2016;1378:11–19.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  54. 54.

    Miller WG, Sandberg S. Quality control of the analytical examination process. In: Rifai N, Horvath AR, Wittwer C, editors. Tietz textbook of clinical chemistry and molecular diagnostics. 6th ed. St. Louis: Elsevier; 2018. p. 121–156.

  55. 55.

    Abdenur JE, Chamoles NA, Guinle AE, Schenone AB, Fuertes AN. Diagnosis of isovaleric acidaemia by tandem mass spectrometry: false positive result due to pivaloylcarnitine in a newborn screening programme. J Inherit Metab Dis. 1998;21:624–630.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  56. 56.

    Vianey-Saban C, Boyer S, Levrat V, et al. Interference of ceoftaxime in plasma acylcarnitine profile mimicking an increase of 3-hydroxypalmitoleylcarnitine (C16:1-OH) using butyl esters. J Inherit Metab Dis. 2004;27(Suppl):94.

    Google Scholar 

  57. 57.

    Kratz LE, Albert JS. 2-Ethylhexanoic acid, found in common plasticizers, leads to an artificial increase in C8 acylcarnitine levels in two neonates treated with extracorporeal membrane oxygenation (ECMO). Clin Chim Acta. 2016;461:59–60.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  58. 58.

    Chace DH, De Jesus VR, Lim TH, Hannon WH, Spitzer AR. Tandem mass spectrometric identification of dextrose markers in dried-blood spots from infants receiving total parenteral nutrition. Clin Chim Acta. 2010;411:1806–1816.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  59. 59.

    Iacobazzi V, Pasquali M, Singh R, et al. Response to therapy in carnitine/acylcarnitine translocase (CACT) deficiency due to a novel missense mutation. Am J Med Genet A. 2004;126A:150–155.

    PubMed  Article  PubMed Central  Google Scholar 

  60. 60.

    Rizzo C, Boenzi S, Inglese R, et al. Measurement of succinyl-carnitine and methylmalonyl-carnitine on dried blood spot by liquid chromatography-tandem mass spectrometry. Clin Chim Acta. 2014;429:30–33.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  61. 61.

    Kamijo T, Indo Y, Souri M, et al. Medium chain 3-ketoacyl-coenzyme A thiolase deficiency: a new disorder of mitochondrial fatty acid beta-oxidation. Pediatr Res. 1997;42:569–576.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

Download references


Members of the ACMG Biochemical Genetics Subcommittee and the Laboratory Quality Assurance Committee reviewed and endorsed this revised document.

Author information




Ethics declarations


All authors (M.J.M., D.O., K.C-O., and S.Y.) work for clinical laboratories that offer acylcarnitine analysis as a clinical service.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


This technical standard is designed primarily as an educational resource for clinical laboratory geneticists to help them provide quality clinical laboratory genetic services. Adherence to this technical standard is voluntary and does not necessarily assure a successful medical outcome. This technical standard should not be considered inclusive of all proper procedures and tests or exclusive of other procedures and tests that are reasonably directed to obtaining the same results. In determining the propriety of any specific procedure or test, the clinical laboratory geneticist should apply his or her professional judgment to the specific circumstances presented by the individual patient or specimen.

Clinical laboratory geneticists are encouraged to document in the patient’s record the rationale for the use of a particular procedure or test, whether or not it is in conformance with this technical standard. They also are advised to take notice of the date any particular technical standard was adopted, and to consider other relevant medical and scientific information that becomes available after that date. It also would be prudent to consider whether intellectual property interests may restrict the performance of certain tests and other procedures.

The Board of Directors of the American College of Medical Genetics and Genomics approved this technical standard on 24 August 2020.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Miller, M.J., Cusmano-Ozog, K., Oglesbee, D. et al. Laboratory analysis of acylcarnitines, 2020 update: a technical standard of the American College of Medical Genetics and Genomics (ACMG). Genet Med (2020).

Download citation


  • clinical genetic testing
  • fatty acid oxidation disorders
  • organic acidemias
  • acylcarnitine
  • tandem mass spectrometry